A multiplex real-time reverse transcription polymerase chain reaction assay for differentiation of classical and variant II strains of avian infectious bronchitis virus

Sara M. Ameen1 · Amany Adel1 · Abdullah Selim1 · Asmaa Magouz2 · Mohammed AboElKhair3 · AbdelHamid H. Bazid2

Received: 1 April 2022 / Accepted: 29 July 2022 / Published online: 29 September 2022
© The Author(s) 2022

Abstract
Identification of avian infectious bronchitis virus (IBV) genotypes is essential for controlling infectious bronchitis (IB) disease, because vaccines that differ from the circulating strains might not provide efficient cross-protection. In Egypt, IBV strain typing is a difficult process, due to the widespread distribution of four genotype lineages (GI-13, GI-23, GI-1, and GI-16), which may contribute to IBV vaccination failure. In this study, we developed a multiplex real-time quantitative reverse transcription polymerase chain reaction (mRT-qPCR) assay that targets highly conserved areas of the S1 gene in order to detect classical (G1) and Egyptian variant II (G23) strains in allantoic fluids and clinical samples. The viral genotyping technique was assessed using commercially available vaccines as well as local strains, and 16 field isolates were tested to investigate its clinical applicability. The assay was found to be specific for the detection of classical and VAR II strains and did not detect the VAR I strain or other avian pathogens such as Newcastle disease virus, avian influenza virus (H9N2 and H5N8), or infectious bursal disease virus. The results also showed that 28 out of 41 samples tested positive for IBV utilizing rt-qRT-PCR targeting the N gene and that 26 out of the 28 positive samples were genotyped by mRT-qPCR targeting the S1 gene, whereas the remaining two samples that were not genotyped were VAR 1 (4/91) and VAR I (793/B). Interestingly, the testing could identify combined infections in one sample, indicating a mixed infection with both genotypes. The real-time RT-PCR assay could detect viral RNA at concentrations as low as $10^2$ EID$_{50}$/ml for both classical and variant II. This assay is rapid, specific, and sensitive. It appears to be a valuable tool for regular disease monitoring that can be used to differentiate as well as identify viruses.

Introduction
Infectious bronchitis (IB) is a highly infectious viral illness that affects the poultry industry around the world [1]. It causes significant economic damage to the poultry sector, even in areas with no velogenic Newcastle disease viruses or pathogenic avian influenza viruses [2]. The illness manifests itself clinically in a variety of ways, predominantly impacting the respiratory system and causing lesions in the reproductive, digestive, and urinary tracts [3]. Although chickens of all ages can be infected with IBV, younger birds are more susceptible than older ones [4]. The etiological
agent of IB is infectious bronchitis virus (IBV), a member of the genus *Gammacoronavirus*, family *Coronaviridae* [5]. IBV has a 27.6-kb positive-sense single-stranded RNA viral genome, which encodes four structural proteins: a spike (S) glycoprotein, an envelope protein, a phosphorylated nucleocapsid protein, and a membrane glycoprotein [6]. The S protein is located on the exterior surface of the envelope of the IBV virion and is cleaved into S1 and S2 subunits by a cellular protease during viral maturation [7]. Determinants of serotype specificity and cell attachment, and epitopes for neutralising antibodies are present in the S1 subunit [8]. The S2 component mediates membrane fusion and connects the S1 protein to the viral membrane.

The S1 subunit exhibits more nucleotide sequence variability than S2, and most of this variability occurs within three distinct hypervariable regions (HVRs) consisting of amino acids 38–67, 91–141, and 274–387 (HVR1, HVR2, and HVR3, respectively) [9]. According to Valastro et al. [10], IBV has been subdivided into six primary genotypes (GI to GVI) in addition to 32 subgenotypic lineages as well as some possible groupings represented as distinct variants according to a classification system based on the S1 sequences.

Four genotype lineages with different genetic and pathogenic features have been reported on chicken farms in Egypt. GI-1 includes the classical wild strains and the vaccine-like strains. GI-23 includes both of the Egyptian variant subgroups (Egy/Var-2 and Egy/Var-1). GI-16, including QX IBV, was first isolated in China and is now found in other Asian countries, Africa, the Middle East, and Europe. GI-13, including the 4/91-like strains, is hypothesized to have been derived from the presently used 4/91 vaccine strain [11].

Genotyping is the most frequently used approach for categorization of IBV strains [12]. Reverse transcription polymerase chain reaction (RT-PCR) is used in molecular analysis to identify viral RNA directly in clinical samples or viruses obtained in a laboratory host system. When using RT-PCR to amplify the IBV S gene, this may be combined with nucleic acid sequencing or restriction fragment length polymorphism (RFLP) analysis in order to determine the virus type [13–17]. Other genotype-specific RT-PCR techniques (real-time or classical) for rapid molecular identification of field variant strains and vaccine strains are also available [18–21].

In Egypt, RT-PCR accompanied by complete or partial S1 gene sequencing has been used to detect and characterise IBV strains [22], prompting us to develop an mRT-qPCR assay that can be used for rapid detection of particular IBV types and can be performed on clinical samples.

## Materials and methods

### Virus strains and clinical samples

Forty-one samples were used to evaluate the assay’s applicability for strain typing. In this work, several panels of reference materials as well as clinical samples were employed for analytical specificity testing and validation of the assay. Analytical specificity was assessed using reference strains for four other avian pathogens (influenza A virus H9N2 and H5N8, Newcastle disease virus [NDV], and infectious bursal disease virus [IBDV]), three IB vaccines (MEVAC IB VAR2, AVI IB H-120, and IB 4/91), and nine IBV-negative samples.

Kidneys, lungs, and cloacal and tracheal swabs were among the nine clinical samples taken from broiler, breeder, and layer chicken flocks with clinical signs of IB. In addition, 16 IBV isolates were used to evaluate the performance of the mRT-qPCR assay. The clinical sample collection was obtained in 2021 and stored at -20°C for subsequent processing. The IBV isolates were supplied by the Reference Laboratory for Veterinary Quality Control on Poultry Production (RLQP) and were also isolated in 2021. Details about reference strains of other avian pathogens and vaccines used in this study are shown in Table 1.

### Extraction of viral nucleic acid

Viral RNA was extracted according to the instruction manual of the EasyPure Viral RNA/DNA Extraction Kit (Trans,

### Table 1 Vaccines and reference strains of other avian pathogens used for testing analytical specificity

| Virus       | Isolate/vaccine       | Origin          | Accession no.       |
|-------------|-----------------------|-----------------|---------------------|
| IBV         | MEVAC VAR II vaccine  | MEVAC           |                     |
| IBV         | AVI IB H-120 vaccine  | Laprovet-France |                     |
| IBV         | Var 1 (4/91) vaccine  | Nobilis         |                     |
| AIV         | A/Turkey/Egypt/A2/2021(H5N8) | RLQP-AHRI | OK160062            |
| AIV         | A/chicken/Egypt/FAO-S33/2021(H9N2) | RLQP-AHRI | OK148893            |
| NDV         | Avian orthoavulavirus 1 fusion protein gene (NDV) | RLQP-AHRI | MZ409479            |
| IBDV        | Infectious bursal disease virus segment A VP2 gene (IBDV) | RLQP-AHRI | MZ409478            |

AIV, avian influenza virus; NDV, Newcastle disease virus; IBDV, infectious bursal disease
catalog no. ER201-01). The extracted viral RNA was stored at -20 °C until examination.

**Primer design for multiplex real-time RT-PCR**

Probes and primers were designed to distinguish between classical and variant II strains. In addition, customised probes and primers for each genotype were designed based on the most conserved region of the S1 gene of each genotype. Bioedit software (http://www.mbio.ncsu.edu/bioedit) was used to extract and align the S1 gene sequences of IBV classical and variant II strains. The alignment included sequences of five classical genotype field isolates (KC533681, AY135205, KU979009, KJ425497, and DQ487085), 13 variant II genotype field isolates (KU979010, EU780077, JX027070, KU979007, KU979008, KU238171, KU979006, JX173489, KY805846, KC533682, and KC533684, KC533683, and MG233398), and the reference strains Ma5 (KY626045), D274 (MH021175), H-120 (FJ888351), and Mass 41 (GQ504725). The specificity of probes and primers was verified by Basic Local Alignment Search Tool (BLAST) search (www.blast.ncbi.nlm.nih.gov) of the GenBank database. Secondary structures and primer dimers were also predicted using the OligoCalc server (http://biotools.nubic.northeastern.edu/OligoCalc.html). The sequences of probes and primers used in this study are shown in Table 2. All of the probes and primers were synthesized by Metabion International AG, Germany.

**IBV detection by real-time RT-PCR targeting the N gene**

We used real-time RT-PCR targeting the N gene because it has been shown to be a sensitive and accurate method for direct detection of IBV in tracheal or cloacal swabs, as well as in allantoic fluid from infected embryonated eggs [23]. The sequences of the primers and probes targeting the N gene are listed in Table 3.

![Image](https://example.com/image.png)

**Table 2** Sequences of primers and probes used in the multiplex system

| Set          | Primer ID       | Sequence (5’-3’)                          | Position in the spike gene |
|--------------|-----------------|-------------------------------------------|---------------------------|
| Variant II   | IBV-VAR II-F+   | 5’-CAA TGG TCC CCG TTT GTG-3’             | 1128-1145                 |
|              | IBV-VAR II-R    | 5’-GTC TAG GAT GGC TAA ACC AC-3’          | 1385-1404                 |
|              | IBV-VAR II-pro+ | (HEX) 5’-CCA GGA ATG AAC CAC TGG TGT TAA CTC-3’ (TAMRA) | 1235-1261                 |
| Classical    | IBV-Class-F+    | 5’-CAT GGT GGT GTT GTG TAT AC-3’          | 211-232                   |
|              | IBV-Class-R     | 5’-ACA CGT ATA GAA TGC TGT TGA AGC-3’     | 375-398                   |
|              | IBV-Class-pro+  | (FAM) 5’-CAG GTA TGG CTT GGT CTACGAGTC-3’ (TAMRA) | 263-288                   |

**Uniplex and multiplex real-time RT-PCR targeting the S1 gene**

Real-time RT-PCR was performed using the primers and probes shown in Table 2. Following the instructions of the kit manufacturer, the qRT-PCR mixes were made as follows: 12.5 µl of 2x one-step qPCR mix, 1.25 µl of RT enhancer, 0.25 µl of Verso enzyme mix, 0.5 µl of each of the forward and reverse primers (50 pmol per primer), 0.125 µl of each probe (30 pmol per probe), and 3 µl of RNA, and the total volume of each reaction was adjusted to 25 µl using PCR-grade water. The following thermal profile was used: 15 min at 50°C for cDNA synthesis and 15 min at 95°C for thermo start activation, followed by 40 cycles of denaturation for 15 s at 95°C, extension, and annealing for 1 min at 60°C for standard uniplex IBV detection and 54°C for our multiplex system.

**Analytical specificity of uniplex and multiplex real-time RT-PCR assays**

Two sets of primers and probes were designed specifically for distinguishing the strains under investigation and tested and optimized separately on the respective IBV types and then cross-tested for their specificity.

![Image](https://example.com/image.png)

**Table 3** Sequences of primers and probes used in real-time RT-PCR targeting the N gene

| ID           | Sequence                          | Position in the N gene |
|--------------|-----------------------------------|------------------------|
| AIBV-fr      | 5’-ATGCTCAACCTTGTCCCT AGCA-3’     | 811-832                |
| AIBV-as      | 5’-TCAAACGTGGATCATCA CGT-3’       | 921-941                |
| TaqMan® probe| FAM TTGGAAGTAGAGTGACGC CCAA-3’ BHQ1 | 848-875               |
Analytical sensitivity of real-time RT-PCR

The detection limit of the rt qRT-PCR was determined by testing in duplicate serial tenfold dilutions of the classical IBV vaccine (H120) and variant II IBV strain (F211), which were adjusted to 10⁷ 50% egg infective dose (EID₅₀)/ml for both, and standard curves were generated. The detection limit was compared with that of real-time RT-PCR targeting the N gene for both strains. The detection limit was defined as the final dilution at which all tested duplicates could be detected.

Amplification of the S1 gene of IBV

The genotypes of the viruses in mRT-qPCR-positive samples were determined based on partial sequences of the spike (S1) gene. Briefly, RNA was amplified by conventional RT-PCR, using specific primers for partial identification of the S1 gene [24] (Table 4). RT-PCR was performed using an Easyscript one-step RT-PCR kit (Trans, catalog no. AE411-02) following the kit instructions. Each reaction contained 10 µl of 2x master mix, 1 µl of each primer at a concentration of 20 pmol, 0.4 µl of RT enzyme, 5 µl of each RNA, and PCR-grade water to a final volume of 20 µl. The reaction mixtures were then incubated in a thermocycler with the following thermal profile: 45°C for 30 minutes for the reverse transcription step and 94°C for 15 minutes for RT inactivation, followed by 40 cycles of denaturation at 94°C for 45 seconds, annealing for 45 seconds at 50°C, and amplification for one min at 72°C, and then an extension step for one cycle at 72°C for 10 min.

Partial sequence of spike gene of IBV

A portion of the S1 gene was sequenced by the Sanger method [25]. BioEdit version 7.0 was used for reading the output sequences and for creating a multiple sequence alignment (accessed in October 2021) [26]. The alignment was then used for constructing neighbor-joining phylogenetic trees using the distance-based method in MEGA version 11 [27].

Table 4 Sequences of primers used for conventional RT-PCR for identification of the S1 gene

| IBV-F20826   | GTTTTATAACTTAACAGFT (RLQP) |
| IBV-R21298   | ATTATAATAACCACCTCTGAG (RLQP) |

Results

A real-time RT-PCR assay targeting the conserved N gene

A real-time RT-PCR that targets the highly conserved N gene was applied to 41 samples to detect IBV, and 28 (nine clinical samples, 16 isolates, and three commercial vaccines) were found to be IBV positive, with Cᵥ values between 13 and 31.78.

Analytical specificity of the uniplex real-time RT-PCR

The specificity of each probe and primer set was initially examined in silico using a BLAST search on the NCBI website. A uniplex RT-qPCR was performed to ensure the workability of each set. Variant II RT-qPCR was able to detect VAR II isolate F211 (GenBank accession no. OK181112), isolate F348, and MEVAC VAR II vaccine, showing no specific amplification of H5N8, H9N2, ND, IBD, VAR I vaccine, H120 vaccine, or the negative control samples, while classical RT-qPCR showed positivity for the H120 vaccine, but it could not detect VAR II isolates (F211 and F348), H5N8, H9N2, ND, IBD, VAR I, MEVAC VAR II vaccine, or the negative control sample. The findings showed that the assay was highly specific with no cross-reactivity (Fig. 1).

Analytical specificity of the multiplex assay

mRT-qPCR detects several targets in one assay. The assay was able to detect two vaccines (MEVAC VAR II and AVI H120 classical vaccines) but gave negative results for the VAR I (4/91) vaccine and other avian pathogens (H5N8, H9N2, NDV, and IBDV). In addition, nine IBV-negative field samples also showed no specific amplification.

Analytical sensitivity of the uniplex RT-qPCR

The average Cᵥ values obtained with duplicates of each dilution revealed that the lowest viral load detected by classical RT-qPCR and variant II RT-qPCR for their particular strains was 10² EID₅₀ per ml. The two assays showed the same sensitivity as the real-time RT-PCR assay targeting the N gene to detect IBV (Table 5). The standard curves for determining the average copy numbers of the serial dilutions of both classical and variant II reference strains had high R² values (0.98 and 0.94, respectively), as shown in Figure 2, indicating that the use of these primers yielded accurate results.

Applying mRT-qPCR to isolates and clinical samples

The mRT-qPCR assay was carried out on 25 clinical samples and isolates, and the results demonstrated that 22 samples
were positive for the variant II genotype (15/16 IBV isolates, 7/9 clinical samples), with $C_t$ values ranging from 12.87 to 31. One sample (1/9) was positive for the classical genotype (sample code: 19), with a $C_t$ value of 28.24. The assay also detected a mixed infection by both genotypes in one sample (1/16) (sample code: 49), which was positive for classical and variant II genotypes, with $C_t$ values of 21.10 and 18.98, respectively (Fig. 3). A field sample previously known as Var I (793/B) (1/9) was tested by mRT-qPCR, and the result was negative (Table 6).

**Partial sequence of the spike gene of IBV**

The amplified RT-PCR products of 13 typed samples (four clinical samples and nine isolates) were purified and sequenced. Sequences produced in this investigation were submitted to the GenBank database, and their accession numbers are listed in Table 7. Phylogenetic analysis demonstrated that the 13 IBV-positive samples clustered with Egyptian variant II sequences (Fig. 4).

---

**Fig. 1** Amplification curves for classical RT-qPCR, showing detection of H120 ($C_t$ 20.49) (A), and variant II RT-qPCR, showing amplification of VAR II with sample code F211 ($C_t$ 17.29) (B). Neither showed amplification of RNA of H5N8, H9N2, NDV, IBDV, VAR I, or RNA from a negative sample.
Discussion

IBV causes a severe, highly contagious infectious illness in chickens. IBV is distributed worldwide and causes substantial economic losses in the poultry sector. Genotyping of IBV depends on polymorphisms in the S gene, which codes for the spike protein, particularly in the S1 fragment [3, 10, 28]. S1 gene sequences are highly variable, and mutations in this region may lead to changes in antigenicity [29]. Typing of circulating strains in the field is crucial for selecting appropriate vaccine(s) for controlling the disease [20].

In Egypt, IBV has been spreading among chickens for the past two decades, inflicting massive economic losses to the poultry sector. Numerous IBV genotypes, including GI-23, GI-16, GI-13, and GI-1, have been identified in Egypt, each with unique pathogenic and genetic characteristics [11]. This study presents the development of a multiplex assay for the specific identification of classical (G1) and variant II (G23) IBV genotypes circulating in Egyptian poultry flocks, along with its validation using field samples. The assay was designed based on highly conserved portions of the S1 gene that can be used to distinguish genotypes [20, 21, 30, 31].

This newly designed system was validated using 41 samples (clinical samples, isolates, vaccines, and reference strains of other avian pathogens). A real-time RT-PCR that targets the highly conserved N gene [23] was used as a reference method to evaluate the newly developed real-time RT-PCR assay. All isolates supplied by RLQP, clinical samples collected from birds with clinical signs of IB, and vaccines were positive for IBV, while those collected from birds with no clinical signs of IB and those with other avian viruses were negative.

Two independent real-time RT-PCR assays were conducted to identify classical and variant II genotypes discovered in chickens, and the results showed that the assays were precise with no cross-reactivity. Both assays gave negative results for the VAR I vaccine (4/91) and other avian pathogens, including (H5N8, H9N2, NDV, and IBDV), indicating the specificity of each system. These assays could directly identify and distinguish those genotypes in allantoic fluids and clinical samples. These findings demonstrate the added value of genotype-specific real-time RT-PCR for molecular typing of IBV in Egypt, as was shown in a Brazilian study in which worked Mass RT-qPCR and BR RT-qPCR were developed and validated [31]. Both assays could identify the BR and Mass genotypes in clinical samples and allantoic fluids, allowing easy and rapid molecular typing of IBV. Compared to the uniplex RT-qPCR system, the mRT-qPCR assay reduces both cost and time, since it detects several targets in a single reaction [32, 33]. The analytical specificity of the assay was evaluated by assessing its capacity to identify and distinguish both VAR II and classical genotypes.

| EID<sub>50</sub> concentration | Classical RT-qPCR (Ct) | Variant II RT-qPCR (Ct) | A Ct: average cycle threshold |
|------------------------------|------------------------|-------------------------|-------------------------------|
| 10<sup>6</sup>               | 20.4                   | 19.5                    | 15.7                          |
| 10<sup>5</sup>               | 23.5                   | 23.5                    | 18.7                          |
| 10<sup>4</sup>               | 26.3                   | 28.2                    | 22.5                          |
| 10<sup>3</sup>               | 29.9                   | 31.5                    | 24.7                          |
| 10<sup>2</sup>               | 32.4                   | 32.4                    | 30.5                          |
| 10<sup>1</sup>               | 34.8                   | 35.07                   | 35.7                          |
| 10<sup>0</sup>               | Negative               | Negative                | Negative                      |
| 10<sup>-1</sup>              | Negative               | Negative                | Negative                      |

*Table 5: Analytical sensitivity of real-time RT-PCR assays targeting the S1 and N genes of classical (H120 vaccine) and variant II (F211) IBV viruses.*
Fig. 2  Detection limit and standard curves of the IBV real-time RT-PCR assays for the classical (A, B) and variant II (C, D) genotypes. Each point represents the average C_t values for duplicates of each dilution. The coefficient of determination ($R^2$) and the amplification efficiency (E) of each assay are indicated.
The designed mRT-qPCR was specific for classical and variant II strains, but it could not detect VAR I (4/91) or VAR I (793/B) strains. In addition, there was no cross-reactivity with IBV-negative samples or with samples containing viruses other than IBV. These results indicate that the multiplex assay is specific, as target strains were simultaneously.
identified without indication of cross-reactivity between probes and primers, as confirmed by the rRT-PCR assay to distinguish Mass and non-Mass serotypes simultaneously. The assay identified all the strains of IBV among the IBV Mass and non-Mass strains [20].

The detection limit was determined using $10^7$ EID$_{50}$/ml of both classical and VAR II strains as a starting concentration. The assay could identify viral RNA to a dilution of $10^{-5}$ for both classical and VAR II strains, while the Mass BR RT-qPCR and RT-qPCR, designed to differentiate between BR and Mass genotypes in Brazil, were able to detect viral RNA up to a dilution $2.4 \times 10^{-6}$ [31]. In comparison with the real-time RT-PCR targeting the conserved N gene, classical RT-qPCR and variant II RT-qPCR exhibited almost the same sensitivity. The differences in $C_t$ values in the real-time RT-PCR targeting the N gene at the same dilution in two experiments were not significant. The difference did not exceed 0.5, which is an acceptable limit that does not adversely affect the accuracy of the results. This difference might have been due to the handling of the sample during the assay. Meanwhile, the differences in $C_t$ values in the Var II vs. classical primer and probes at the same dilution in the sensitivity testing may have been related to the size of the amplicon in each system and its CG content [34]. It has been found that the size of the amplicon in real-time TaqMan probe PCR affects the efficiency of detection. Increasing the amplicon size reduces the sensitivity of detection, thereby increasing the $C_t$ value [35].

The newly designed assay could directly identify and distinguish these genotypes in clinical samples. Among the IBV-positive samples, 92% (24/28) were categorized as VAR II strains, demonstrating that the assay is useful for rapid diagnosis of disease. In general, one of the most significant advantages of mRT-qPCR is its potential to identify coinfections. The newly developed assay identified a mixed infection in sample 49 (Fig. 3), which was positive for both genotypes, suggesting a combined infection with the VAR II and classical genotypes. In a previous study [31], a sample with a mixed infection of the Mass and BR genotypes was reported.

Partial S1 gene analysis has been used in previous studies for confirmation of genotype-specific RT-PCR results [19]. In this study, 13 samples were tested by partial S1 gene sequencing, and the results obtained by mRT-qPCR were consistent with those obtained by sequencing and phylogenetic analysis. The isolates from this study are phylogenetically and genetically closely related to Egyptian variant II (13/13, 100%), which indicates the specificity and accuracy of the developed system and agrees with the study of Chen and Wang, who showed that 11 isolates were accurately genotyped by the mRT-PCR assay, in agreement with viral genome sequencing (11/11, 100%) [19].
### Table 6

Comparative Ct values of the mRT-qPCR targeting the S1 gene and real-time RT-PCR targeting the conserved N gene in clinical samples and isolates for this study.

| Sample code | Sample type | Ct (dRn) of the N gene system | Ct (dRn) of the VAR II system | Ct (dRn) of the classical system | Genotype |
|-------------|-------------|------------------------------|-------------------------------|-------------------------------|----------|
| IBV-13      | Organs      | 24                           | 24.12                         | Negative                      |
| IBV-19      | Organs      | 27                           | Negative                      | 28.24                         |
| Egy/IBV-23  | Swabs       | 17.94                        | 20.44                         | Negative                      |
| Egy/IBV-24  | Swabs       | 20.13                        | 22.52                         | Negative                      |
| Egy/IBV-25  | Swabs       | 20.37                        | 23.07                         | Negative                      |
| Egy/IBV-26  | Organs      | 21.68                        | 22.89                         | Negative                      |
| IBV-27      | Organs      | 25.85                        | 24.46                         | Negative                      |
| IBV-28      | Organs      | 22.83                        | 24.15                         | Negative                      |
| IBV-35      | Isolate     | 29.56                        | 28.2                          | Negative                      |
| Egy/IBV-36  | Isolate     | 22.1                         | 21.18                         | Negative                      |
| IBV-37      | Isolate     | 31.14                        | 29.94                         | Negative                      |
| Egy/IBV-38  | Isolate     | 17.48                        | 17.78                         | Negative                      |
| Egy/IBV-39  | Isolate     | 21.47                        | 18.05                         | Negative                      |
| IBV-40      | Isolate     | 31.78                        | 30.58                         | Negative                      |
| IBV-41      | Isolate     | 30.88                        | 31                            | Negative                      |
| Egy/IBV-43  | Isolate     | 23.02                        | 18.68                         | Negative                      |
| IBV-44      | Isolate     | 27.68                        | 26.18                         | Negative                      |
| Egy/IBV-46  | Isolate     | 21.73                        | 18.68                         | Negative                      |
| Egy/IBV-47  | Isolate     | 21.38                        | 20.32                         | Negative                      |
| Egy/IBV-48  | Isolate     | 23.01                        | 21.84                         | Negative                      |
| IBV-49      | Isolate     | 19.92                        | 19.98                         | 21.10                         |
| Egy/IBV-50  | Isolate     | 25.72                        | 23.87                         | Negative                      |
| F211        | Isolate     | 13                           | 19.20                         | Negative                      |
| Var I (793/B) | Organs     | 19                           | Negative                      | Negative                      |
| MEVAC VAR II | Vaccine    | 21                           | 21.19                         | Negative                      |
| H120        | Vaccine     | 19                           | Negative                      | 19.38                         |
| Var I (4/91) | Vaccine    | 19.3                         | 19.3                          | Negative                      |
| H5N8        | Reference strain | Negative                | Negative                      | Negative                      |
| H9N2        | Reference strain | Negative                | Negative                      | Negative                      |
| ND          | Reference strain | Negative                | Negative                      | Negative                      |
| IBD         | Reference strain | Negative                | Negative                      | Negative                      |

### Table 7

Sequenced IBV isolates and clinical samples and their GenBank accession numbers.

| Sample code | Sample type | Ct (dRn) of the N gene system | Ct (dRn) of the VAR II system | Ct (dRn) of the classical system | Genotype | GenBank accession no. |
|-------------|-------------|------------------------------|-------------------------------|-------------------------------|----------|----------------------|
| Egy/IBV-23  | Swabs       | 17.94                        | 20.44                         | Negative                      | VAR II   | OL691928             |
| Egy/IBV-24  | Swabs       | 20.13                        | 22.52                         | Negative                      | VAR II   | OL691929             |
| Egy/IBV-25  | Swabs       | 20.37                        | 23.07                         | Negative                      | VAR II   | OL691930             |
| Egy/IBV-26  | Swabs       | 21.68                        | 22.89                         | Negative                      | VAR II   | OL691931             |
| Egy/IBV-36  | Swabs       | 22.1                         | 21.18                         | Negative                      | VAR II   | OL691932             |
| Egy/IBV-39  | Swabs       | 17.48                        | 17.78                         | Negative                      | VAR II   | OL691933             |
| Egy/IBV-37  | Organs      | 21.47                        | 18.05                         | Negative                      | VAR II   | OL691934             |
| Egy/IBV-38  | Swabs       | 23.02                        | 18.68                         | Negative                      | VAR II   | OL691935             |
| Egy/IBV-39  | Swabs       | 21.73                        | 18.68                         | Negative                      | VAR II   | OL691936             |
| Egy/IBV-47  | Swabs       | 21.38                        | 20.32                         | Negative                      | VAR II   | OL691926             |
| Egy/IBV-48  | Isolate     | 23.01                        | 21.84                         | Negative                      | VAR II   | OL691927             |
| F211        | Isolate     | 25.72                        | 23.87                         | Negative                      | VAR II   | OL691937             |
| H120        | Vaccine     | 13                           | 19.20                         | Negative                      | VAR II   | OK181112             |
Real-time RT-PCR assay for avian infectious bronchitis virus

Conclusion

The mRT-qPCR assay targeting the S1 gene is a promising assay for obtaining rapid, sensitive, and precise results for discriminating between classical and variant II genotypes of IBV.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00705-022-05603-7.

Acknowledgments The authors gratefully acknowledge Dr. Naglaa Haggag (Reference Laboratory for Veterinary Quality Control on Poultry Production, Animal Health Research Institute, Agricultural Research Centre) for her extensive technical support.

Author contributions Designed research and prepared the manuscript: SMA, AA, and AS. Performed research: SMA, AA. Wrote the paper: All authors have read and agreed to the published version of the manuscript. Data availability: All data generated or analyzed in this study are included in this published article.

Funding Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Fig. 4 Phylogenetic tree based on partial amino acid sequences of the S1 genes of 13 IBV clinical samples and isolates (indicated by black dots) and those of other related infectious bronchitis viruses and reference strains.
Compliance with ethical standards

**Conflict of interest** All authors declare that they have no conflict of interest.

**Ethical approval** This article does not contain any studies with animals performed by any of the authors.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. de Wit JJ, Cook JKA (2019) Spotlight on avian pathology: infectious bronchitis virus. Avian Pathol 48:393–395
2. Cook JKA, Jackwood M, Jones RC (2012) The long view: 40 years of infectious bronchitis research. Avian Pathol 41:239–250
3. Cavanagh D (2007) Coronavirus avian infectious bronchitis virus. Vet Res 38:281–297
4. Crinion RAP, Holstad MS (1972) Pathogenicity of four serotypes of avian infectious bronchitis virus for the oviduct of young chickens of various ages. Avian Dis 16(2):351–363
5. de Groot RJ, Baker SC, Baric R, Enjuanes L, Gorbalenya AE, Holmes KV, Perlman S, Poon L, Rottier PJ, Talbot PJ, Woo PC (2012) Family Coronaviridae, p 806–828. Virus Taxonomy, Ninth Report of the International Committee on Taxonomy of Viruses Acad Press San Diego, CA
6. Stern DF, Sefton BM (1982) Coronavirus proteins: biogenesis of avian infectious bronchitis virus virion proteins. J Virol 44:794–803
7. Armesto M, Cavanagh D, Britton P (2009) The replicate gene of avian coronavirus infectious bronchitis virus is a determinant of pathogenicity. PLoS ONE 4:e7384
8. Ignjatovic J, Galli L (1994) The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens. Arch Virol 138:117–134
9. Shan D, Fang S, Han Z et al (2018) Effects of hypervariable regions in spike protein on pathogenicity, tropism, and serotypes of infectious bronchitis virus. Virus Res 250:104–113
10. Valastro V, Holmes EC, Britton P et al (2016) S1 gene-based phylogeny of infectious bronchitis virus: an attempt to harmonize virus classification. Infect Genet Evol 39:349–364
11. Abozeid HH, Naguib MM (2020) Infectious bronchitis virus in Egypt: genetic diversity and vaccination strategies. Vet Sci 7:204
12. De Wit JJ, Cook JKA, Van der Heijden HMJF (2011) Infectious bronchitis virus variants: a review of the history, current situation and control measures. Avian Pathol 40:223–235
13. Cavanagh D, Davis P, Cook J, Li D (1990) Molecular basis of the variation exhibited by avian infectious bronchitis coronavirus (IBV). In: Coronaviruses and their Diseases. Springer, Boston, MA, pp 369–372
14. Kwon HM, Jackwood MW, Gelb J (1993) Jr. Differentiation of infectious bronchitis virus serotypes using polymerase chain reaction and restriction fragment length polymorphism analysis. Avian Dis 37:194–202
15. Jackwood MW, Yousef NMH, Hilt DA (1997) Further development and use of a molecular serotype identification test for infectious bronchitis virus. Avian Dis 41(1):105–110
16. Keeler CL Jr, Reed KL, Nix WA, Gelb J Jr (1998) Serotype identification of avian infectious bronchitis virus by RT-PCR of the peplomer (S-1) gene. Avian Dis 42(2):275–284
17. Kingham BF, Keeler CL Jr, Nix WA et al (2000) Identification of avian infectious bronchitis virus by direct automated cycle sequencing of the S-1 gene, Avian Dis 44(2):325–335
18. Handberg KJ, Nielsen OL, Pedersen MW, Jørgensen PH (1999) Detection and strain differentiation of infectious bronchitis virus in tracheal tissues from experimentally infected chickens by reverse transcription-polymerase chain reaction. Comparison with an immunohistochemical technique. Avian Pathol 28:327–335
19. Chen H-W, Wang C-H (2010) A multiplex reverse transcriptase–PCR assay for the genotyping of avian infectious bronchitis viruses. Avian Dis 54:104–108
20. Acevedo AM, Perera CL, Vega A et al (2013) A duplex SYBR Green I-based real-time RT-PCR assay for the simultaneous detection and differentiation of Massachusetts and non-Massachusetts serotypes of infectious bronchitis virus. Mol Cell Probes 27:184–192
21. Roh H-J, Jordan BJ, Hilt DA, Jackwood MW (2014) Detection of infectious bronchitis virus with the use of real-time quantitative reverse transcriptase–PCR and correlation with virus detection in embryonated eggs. Avian Dis 58:398–403
22. Rohaim MA, El Naggar RF, Hamoud MM et al (2019) Emergence and genetic analysis of variant pathogenic 4/91 (serotype 793/B) infectious bronchitis virus in Egypt during 2019. Virus Genes 55:720–725
23. Meir R, Maharat O, Farnushi Y, Simanov L (2010) Development of a real-time TaqMan® RT-PCR assay for the detection of infectious bronchitis virus in chickens, and comparison of RT-PCR and virus isolation. J Virol Methods 163:190–194
24. Zanaty A, Naguib MM, El-Husseiny MH et al (2016) The variation exhibited by avian infectious bronchitis coronavirus (IBV). In: Coronaviruses and their Diseases. Springer, Boston, MA, pp 369–372
25. Kumar S, Stecher G, Li M et al (2018) MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol 35:1547
26. Belouzard S, Millet JK, Licitra BN, Whittaker GR (2012) Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4:1011–1033
27. Holmes KV, Lai MMC (1996) Coronaviridae: the viruses and their replication. Fields Virology: 24:104–108
28. Hall T (2004) BioEdit version 7.0. Distrib by author, website accessed on Oct 2021 www.mbio.ncsu.edu/BioEdit/bioedit.html
29. Sanger F, Nicklen S, Coulson AR (1992) DNA sequencing with chain-terminating inhibitors. 1977. Biotechnology 24:104–108
30. El-Husseiny MH, Zanaty A, Naguib MM et al (2016) The S1 glycoprotein of infectious bronchitis virus circulating in Egypt reveals evidence of intra-genotypic recombination. Arch Virol 161:3583–3587
31. Meir R, Maharat O, Farnushi Y, Simanov L (2010) Development of a real-time TaqMan® RT-PCR assay for the detection of infectious bronchitis virus in chickens, and comparison of RT-PCR and virus isolation. J Virol Methods 163:190–194
32. Zanaty A, Naguib MM, El-Husseiny MH et al (2016) The sequence of the full spike S1 glycoprotein of infectious bronchitis virus circulating in Egypt reveals evidence of intra-genotypic recombination. Arch Virol 161:3583–3587
33. Sanger F, Nicklen S, Coulson AR (1992) DNA sequencing with chain-terminating inhibitors. Biotechnology 24:104–108
34. Hall T (2004) BioEdit version 7.0. Distrib by author, website accessed on Oct 2021 www.mbio.ncsu.edu/BioEdit/bioedit.html
35. Kumar S, Stecher G, Li M et al (2018) MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol 35:1547
36. Belouzard S, Millet JK, Licitra BN, Whittaker GR (2012) Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4:1011–1033
37. Holmes KV, Lai MMC (1996) Coronaviridae: the viruses and their replication. Fields Virology: 24:104–108
38. Roh H-J, Jordan BJ, Hilt DA, Jackwood MW (2013) Simultaneous detection of five major serotypes of Avian coronavirus by a multiplex microsphere-based assay. J Vet Diagnostic Invest 25:458–466
39. Padiha de Fraga A, Ikuta N, Salvador Kazantzi Fonseca A et al (2016) A real-time reverse-transcription polymerase chain reaction for differentiation of Massachusetts vaccine and Brazilian field genotypes of avian infectious bronchitis virus. Avian Dis 60:16–21
40. Ali M, Razzak M, Hamid SBA (2014) Multiplex PCR in species authentication: probability and prospects—a review. Food Anal Methods 7:1933–1949
33. Laamiri N, Aouini R, Marnissi B et al (2018) A multiplex real-time RT-PCR for simultaneous detection of four most common avian respiratory viruses. Virology 515:29–37
34. McCord B, Pionzio A, Thompson R (2015) Analysis of the effect of a variety of PCR inhibitors on the amplification of DNA using real time PCR, melt curves and STR analysis U.S. Department of Justice.
35. Debode F, Marien A, Janssen É, et al (2017) The influence of amplicon length on real-time PCR results. Base 21(1), 3-11

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.